Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 12

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 12
---
 cause us to incur debt 
 obligations to satisfy the payment obligations.                                                                |

| • |     | Competitive products may reduce or eliminate the commercial opportunity for our product candidate for our current                                                                                                                                         
 or future indications. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies are more effective or safer than ours, our ability to develop and successfully commercialize our current products may 
 be adversely affected.                                                                                                                                                                                                                                    |

| • |     | We are dependent on the services of our management and other clinical and scientific personnel, and if we are not                 
 able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. |

| • |     | If we are unable to obtain and maintain sufficient intellectual property protection for our technologies, and                                                                                                                                           
 product candidate and any future product candidates we may develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar 
 or identical to ours, and our ability to successfully develop and commercialize our product candidate may be adversely affected.                                                                                                                        |

| • |     | Patent terms may be inadequate to protect our competitive position on our product candidate for a sufficient 
 amount of time.                                                                                              |

Corporate Information and Trademarks LB Pharmaceuticals Inc was incorporated under the laws of the State of Delaware in September 2015. Our principal executive office is located at One Pennsylvania Plaza, Suite 1025, New York, NY 10119. Our telephone number is (212) 605-0300. Our website address is https://lbpharma.us. Information contained in, or accessible through, our website does not constitute a part of, and is not incorporated into, this prospectus. The LB Pharmaceuticals logo, the name LB Pharmaceuticals, and other trademarks of LB Pharmaceuticals Inc appearing in this prospectus are the property of LB Pharmaceuticals Inc. Solely for convenience, trade names, trademarks, and service marks contained in this prospectus may appear without the “ ®” or “ ™” symbols. Such references are not intended to indicate, in any way, that the respective owners will not assert, to the fullest extent possible under applicable law, their rights to those trade names, trademarks, and service marks. Implications of Being an Emerging Growth Company and a Smaller Reporting Company We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and we may remain an emerging growth company for up to five years